Ji Hai-Gang

Learn More
BACKGROUND Compared with the zotarolimus-eluting stent (ZES), the everolimus-eluting stent (EES) has reduced the risk of stent restenosis and thrombosis as found in a number of randomized-controlled trials (RCTs). However, the benefits have been variable. MATERIALS AND METHODS We evaluate the long-term effect of EES and ZES on the risk of stent thrombosis(More)
  • 1